Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver. Since transplant recipients are at risk for CMV or have evidence of infection with CMV, they are given an antiviral drug (usually ganciclovir or valganciclovir). Despite this, there are a chance that CMV infection may cause problems in the future. The purpose of this study is to assess how well patients'immune systems responds to the CMV virus, so that in the future it may be possible to predict which patients are at highest risk of CMV.
Condition or disease
Procedure: Monitoring-blood samples drawn for CMV testing
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female patients who fulfill the following criteria are eligible for inclusion.
CMV D+/R- liver, kidney and heart recipient
CMV R+ liver,kidney and heart recipients who have received thymoglobulin induction therapy.
D+/R- and R+ lung transplant recipients.
Able to give written informed consent
Are willing and able to comply with the protocol
Age >=18 years
Patient unwilling or unable to give informed consent